Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarMMa Phase 2 Study of bb2121 (idecabtagene vicleucel) in Relapsed and Refractory Multiple Myeloma
jRCT1080224134Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 2, open-label, single-arm trial of idecabtagene vicleucel in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Started Nov 2018; status: completed.
02
Drugs
idecabtagene vicleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT1080224134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224134.